Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. - Wikidata - wikimedia - TriplyDB

Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.

Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.

http://www.wikidata.org/entity/Q36724916

about

The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era Immunity to Infections after Haploidentical Hematopoietic Stem Cell Transplantation Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies.Halfway there: the past, present and future of haploidentical transplantation.Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.Mechanistic approaches for the prevention and treatment of chronic GVHD.Comparable post-relapse outcomes between haploidentical and matched related donor allogeneic stem cell transplantation.Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types.Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion.NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications.Cytokine mediators of chronic graft-versus-host disease.Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes.Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis.T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation.

P2860

Q28072397-635F5E1F-2645-4506-B1E9-9B67DC3AFE17 Q28079606-2CFBC25E-5ADB-4689-AFC9-90837C7D9BB6 Q38823260-4C05426A-F932-4D82-A808-D6670D1D2900 Q38838264-88FDDB79-392A-4E39-B703-98158298A241 Q39002164-636143A8-8796-4DD7-B558-51DBC042B5FA Q39002166-071789B7-8456-4D9A-B4C1-5EF362352D3A Q39232824-CDEDCA71-8104-4FA9-9861-49F9DBC4C8EC Q41092916-35CEF361-4D6D-4F72-8205-B97AC7C8A96A Q47572499-A57208CF-441A-41F8-BC61-C8860930820E Q47847626-2D464A89-C0DC-42D4-AF16-4D3AE42B40A1 Q50915048-FDC3C8B6-B1A3-46F6-9392-A16B6B1C938A Q51783552-C1C8BFFB-70D6-4B68-AAEF-D6AC24A24583 Q53082542-90634D3C-FF84-4332-9A07-7DBF89117DA9 Q55060181-BDE11EC9-709B-4999-B0DE-B5608803D77F

P2860

Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.

http://www.wikidata.org/entity/Q36724916

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Haploidentical bone marrow and ...... nsplantation cyclophosphamide.

@ast

Haploidentical bone marrow and ...... nsplantation cyclophosphamide.

@en

type

label

Haploidentical bone marrow and ...... nsplantation cyclophosphamide.

@ast

Haploidentical bone marrow and ...... nsplantation cyclophosphamide.

@en

prefLabel

Haploidentical bone marrow and ...... nsplantation cyclophosphamide.

@ast

Haploidentical bone marrow and ...... nsplantation cyclophosphamide.

@en

P1433

Q36724916-34590ABD-A99E-47F4-9793-A0B3D832BA31

P1476

Q36724916-36921050-C758-46B0-ABC5-8A4F85F7E82E

P2093

Q36724916-341F1E79-FCA0-4873-89EB-7EEE82652429

Q36724916-A1386A2B-21AA-4976-B520-55A26D9D65EE

Q36724916-C3857CD1-5875-4444-B4EC-BB9A1F634FFC

Q36724916-E6BABFED-EF8D-4ADE-80FD-0A416C61624A

P2860

Q36724916-004B3281-4476-461A-B213-495861C9182F

Q36724916-01F6C73B-D31A-4BF4-9A25-DB18B02F7DAF

Q36724916-0629D1EE-B1A5-49B5-96A3-A37206D00734

Q36724916-0F3C487B-E5B2-40ED-8F5E-67487C451CCA

Q36724916-0F713FBA-63FD-435A-AF35-869283DB2789

Q36724916-1C663F8C-D8BF-402A-A0F0-3CC18BC84A18

Q36724916-1D5792AD-BED5-46D5-819F-E74E3C137BD9

Q36724916-239CE139-A7D9-4996-A9F2-97C4B937C2AD

Q36724916-27DCA48C-227B-4296-B42A-79A1140FD064

Q36724916-2F868ED9-615D-4AF5-A904-8380047A93A7

P304

Q36724916-896B5D07-8E2E-4FB0-B3A5-B173C8B0BA78

P31

Q36724916-5A22A255-C399-46C5-AC6E-AA7CBA7B6697

P356

Q36724916-900054DD-8999-45F8-AEDE-7B060F15C214

P433

Q36724916-7974FE01-2F19-4C00-B2A2-93AA7F99601A

P478

Q36724916-0C633A04-4794-4635-B4E9-C8FE02134A8E

P577

Q36724916-6462DAAB-6F39-4814-8CE7-CE22CA85D273

P698

Q36724916-55D9DC8B-91CB-49AD-867F-BF2755E7122E

P932

Q36724916-AFECD9B5-D8C5-4849-B6C3-2967505A2D5F

P356

J.SEMINHEMATOL.2016.01.005

P1433

Seminars in Hematology

P1476

Haploidentical bone marrow and ...... nsplantation cyclophosphamide.

@en

P2093

Ephraim J Fuchs

http://www.w3.org/2001/XMLSchema#string

Leo Luznik

http://www.w3.org/2001/XMLSchema#string

Paul V O'Donnell

http://www.w3.org/2001/XMLSchema#string

Tara M Robinson

http://www.w3.org/2001/XMLSchema#string

P2860

Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.

P304

90-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.SEMINHEMATOL.2016.01.005

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27000732

http://www.w3.org/2001/XMLSchema#string

P932

4806368

http://www.w3.org/2001/XMLSchema#string